Gyre Therapeutics (GYRE) Stock Statistics & Valuation Metrics

Gyre Therapeutics has a market cap or net worth of $649.22M. The enterprise value is $1.05B.

Gyre Therapeutics has 86.33M shares outstanding. The number of shares has decreased by -2.65% in one year.

Gyre Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 11.69%.

The current PE Ratio of Gyre Therapeutics is 85.20. Gyre Therapeutics’s PEG ratio is -0.69.

In the last 12 months, Gyre Therapeutics had revenue of $105.76M and earned $28.54M in profits. Earnings per share was $0.00.

In the last 12 months, operating cash flow was -$3.64M and capital expenditures -$2.31M, giving a free cash flow of -$5.96M billion.

Gyre Therapeutics pays an annual dividend of $3.59, resulting in a dividend yield of

Gyre Therapeutics upcoming earnings date is May 8, 2025, TBA.

Gyre Therapeutics as a current ratio of 3.32, with Debt / Equity ratio of 0.03

In the past 12 months, Gyre Therapeutics has paid $3.17M in taxes.

Gyre Therapeutics EV to EBITDA ratio is 63.07, with an EV/FCF ratio of -171.16.

Gyre Therapeutics has $26.67M in cash and marketable securities with $1.60M in debt, giving a net cash position of -$25.07M billion.

Gross margin is 96.33%, with operating margin of 15.28%, and net profit margin of 11.43%.

The average price target for Gyre Therapeutics is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy